# Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Source: https://onco.cc/trials/nct03334617/  
OnCo record `nct03334617` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Durvalumab, Ceralasertib, Olaparib in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy is a phase 2 interventional study registered as NCT03334617 by AstraZeneca, with 528 participants enrolled, started 2017-12-18 and due to reach its primary completion in 2024-09-13. Interventions recorded: Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03334617
- Phase: 2
- Setting: An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).
- Sponsor: AstraZeneca
- Enrolled: 528

## Sources

- ClinicalTrials.gov NCT03334617: https://clinicaltrials.gov/study/NCT03334617

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Ceralasertib](https://onco.cc/drugs/ceralasertib/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Olaparib](https://onco.cc/drugs/olaparib/), [Oleclumab](https://onco.cc/drugs/oleclumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Vistusertib](https://onco.cc/drugs/vistusertib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct03334617.json